Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
You may also be interested in...
Orteronel Leaves Hole In Millennium/Takeda Pipeline
The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.
Orteronel Leaves Hole In Millennium/Takeda Pipeline
The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.
Baxter Locks Up European Rights To Onconova’s Late-Stage Cancer Drug Rigosertib
For an myelodysplastic syndrome and pancreatic cancer drug, the diversified pharma and device company paid $50 million upfront, plus a generous $515 million in milestones that could pay out before the drug is even commercialized.